Journal article
Clinical significance of CD73 in triple-negative breast cancer: Multiplex analysis of a phase III clinical trial
L Buisseret, S Pommey, B Allard, S Garaud, M Bergeron, I Cousineau, L Ameye, Y Bareche, M Paesmans, JPA Crown, A Di Leo, S Loi, M Piccart-Gebhart, K Willard-Gallo, C Sotiriou, J Stagg
Annals of Oncology | OXFORD UNIV PRESS | Published : 2018
Abstract
Background: CD73 is an ecto-enzyme that promotes tumor immune escape through the production of immunosuppressive extracellular adenosine in the tumor microenvironment. Several CD73 inhibitors and adenosine receptor antagonists are being evaluated in phase I clinical trials. Patients and methods: Full-face sections from formalin-fixed paraffin-embedded primary breast tumors from 122 samples of triple-negative breast cancer (TNBC) from the BIG 02-98 adjuvant phase III clinical trial were included in our analysis. Using multiplex immunofluorescence and image analysis, we assessed CD73 protein expression on tumor cells, tumor-infiltrating leukocytes and stromal cells. We investigated the associa..
View full abstractGrants
Awarded by McGill University
Funding Acknowledgements
This work was supported by a Project Grant from the Canadian Institutes of Health Research (CIHR, grant number: 364476). JS is supported by the Famille Jean-Guy Sabourin Research Chair in Pharmacology. LB is a fellow of the Belgian Fund for Scientific Research (FRS-FNRS).